Ballicules.com

Ritlecitinib

LITFULO

Pronunciation: rit-le-SYE-ti-nib (lit-FUL-oe)

Ritlecitinib ballicule: receptor binding, kinetics and half-life diagram
Mechanism of action: Ritlecitinib ballicule
Ritlecitinib LITFULO mascot mnemonic cartoon
Visual mnemonic: Ritlecitinib mascot
“Little Foo Foo, the Riddle City nibbler”
jack → Janus kinase (JAK) inhibitor

What it isAn oral covalent inhibitor of JAK3 and the TEC kinase family, for severe alopecia areata, including adolescents.

Why this oneIt extends the JAK-inhibitor alopecia story to age twelve and up, with kinase selectivity intended to spare the broader JAK1/2 effects.

What limits itIt still carries the JAK-class warnings — infection, thrombosis, malignancy, cardiovascular events — and hair regrowth reverses if it is stopped; screen for tuberculosis and avoid live vaccines.

Ritlecitinib molecular structure (skeletal formula)
Molecular structure: Ritlecitinib

Ritlecitinib prescription history

Animated chart of estimated U.S. prescriptions per year, Tyrosine kinase inhibitors (2001–2026). Ritlecitinib enters in 2023 (estimated).

Classes and tags

Clinical profile

Therapeutic safety burden3 / 4
Overdose danger1 / 4
Weight-gain liability0 / 4
Sedation liability0 / 4
QT / Torsades0 / 4
Direct muscarinic antagonism0 / 4
Embryofetal risk2 / 4

Legacy pregnancy categoryN/A (post-2015 labeling)

Defining liabilitySerious infection, cytopenias and thrombotic risk

FDA label

BOXED WARNING Serious infections (incl. TB — screen/treat latent TB; monitor); increased all-cause mortality incl. sudden CV death (another JAK inhibitor vs TNF blockers in RA); malignancies (lymphoma, lung cancer); MACE; thrombosis (PE, venous/arterial).
FDA dosingPopulationStartTargetMax
Severe alopecia areataAdults and adolescents ≥12 yr50 mg QD50 mg QD50 mg QD

Renal Undefined

Hepatic No adjustment for mild-moderate (Child-Pugh A-B); not recommended in severe (Child-Pugh C)

Instructions

Available strengths

Cautions

Adverse reactions

Pregnancy Insufficient human data; fetotoxicity/malformations in animals at ≥49x MRHD; exposure registry 1-877-390-2940

Lactation Do not breastfeed during treatment and for ~14 h after last dose (~6 half-lives)

Cost

Ritlecitinib (LITFULO)
Strength#/mogeneric $/moCostPlus
50 mgcap30 qdnot offered
NADAC is a voluntary CMS survey of what retail community pharmacies pay for the drugs they stock. Ritlecitinib is dispensed outside retail pharmacies, so it rarely appears on surveyed invoices.

Open Ritlecitinib in the interactive console ↗

Self-check